New pill takes aim at Hard-to-Treat sarcoma
NCT ID NCT07633756
First seen Jun 09, 2026 · Last updated Jun 23, 2026 · Updated 3 times
Summary
This early-phase trial tests a new oral drug called REC-617 in 15 people with a rare type of sarcoma (leiomyosarcoma) that has spread and no longer responds to standard treatments. The drug targets a protein called CDK7, which may help control tumor growth. The main goal is to check safety and side effects, while also seeing if the drug can shrink or stabilize the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEIOMYOSARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
REC-617 (a CDK7 inhibitor taken by mouth)
What this could lead to
If it works, this could point toward a new treatment option for people with a rare and aggressive type of sarcoma that has stopped responding to other therapies.
What could go wrong
This is a very early, small Phase 1 trial with only 15 people. The main goal is safety, not yet effectiveness. Many early-stage cancer drugs do not end up working in larger studies.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.